"At Genesis Clinical research, we conduct research in a compassionate, professional setting. We strive to increase the quality of life in our patients and to provide the opportunity to access new drugs and medical treatments that may otherwise not be available."

During the past decade, Genesis Clinical Research, LLC ( Site 0003) conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Genesis Clinical Research, LLC ( Site 0003)" #1 sponsor was "Merck Sharp & Dohme LLC" with 2 trials, followed by "Abbott" with 1 trials sponsored, "Amgen" with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "Sandoz" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Genesis Clinical Research, LLC ( Site 0003)" #1 collaborator was "Duke Clinical Research Institute" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Genesis Clinical Research, LLC ( Site 0003)" are "ASCVD" (1 trials), "Anemia" (1 trials), "Chronic Kidney Disease (CKD)" (1 trials), "Diabetic Kidney Disease" (1 trials) and "End-Stage Renal Disease" (1 trials). Many other conditions were trialed in "Genesis Clinical Research, LLC ( Site 0003)" in a lesser frequency.

Most popular intervention types in "Genesis Clinical Research, LLC ( Site 0003)" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "BMS-813160" (1 trials), "HX575 epoetin alfa" (1 trials), "MK-2060" (1 trials), "Molnupiravir" (1 trials) and "Placebo matching with BMS-813160" (1 trials). Other intervention names were less common.

The vast majority of trials in "Genesis Clinical Research, LLC ( Site 0003)" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Genesis Clinical Research, LLC ( Site 0003)". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Genesis Clinical Research, LLC ( Site 0003), undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Genesis Clinical Research, LLC ( Site 0003), 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".